Valeo Pharma (CSE: VPH- OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive to bring news the company now has a commercialization and supply agreement with Novartis Canada for two asthma therapies, Enerzair Breezhaler and Atectura Breezhaler.
Saviuk telling proactive Valeo will be responsible for medical and commercial activities for Enerzair and Atectura for an initial 8 year period. Saviuk saying with these two products, the company is now one of the leading Canadian respiratory companies providing best-in-class asthma therapies.